Hospital
Houlton Regional Hospital
Houlton Regional Hospital was paid $4.18M by Medicaid between Jan 2018 and Dec 2024, across 223 billing codes. Its largest line is 99285, emergency room visit (most serious) — 16% of everything it billed.
33Billing provider infoHOULTON REGIONAL HOSPITAL
HOULTON, ME 04730
HOULTON, ME 04730
33aNPI1508823741assigned 05/01/2006
33bProvider typeCritical Access Hospital
28Total paid$4.18M
24GClaims466,654
24DCodes billed223
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Maine
Rank by total paid#2 of 14
Median peer was paid$1.76M
This provider vs. median2.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,372 | $581K | |
| 2019 | 65,136 | $570K | |
| 2020 | 57,266 | $572K | |
| 2021 | 69,727 | $694K | |
| 2022 | 73,135 | $673K | |
| 2023 | 73,545 | $570K | |
| 2024incomplete | 65,473 | $518K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 16% | 18,078 | 11,022 | $675K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.8% | 3,920 | 1,851 | $325K |
| 70450 | Computed tomography, head or brain; without contrast material | 6.6% | 5,231 | 2,413 | $278K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 6.5% | 7,515 | 5,371 | $272K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.5% | 21,052 | 15,710 | $272K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 5.9% | 3,162 | 1,507 | $245K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.6% | 16,811 | 13,088 | $194K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.7% | 2,488 | 1,216 | $155K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.6% | 5,842 | 4,844 | $151K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 8,737 | 7,446 | $118K |
| 71046 | Radiologic examination, chest; 2 views | 2.7% | 11,939 | 5,510 | $111K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.6% | 11,844 | 10,057 | $110K |
211 more codes
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.3% | 1,635 | $96K |
| G0378 | Hospital observation service, per hour | 2.3% | 676 | $95K |
| 80053 | Comprehensive metabolic panel | 1.7% | 27,892 | $69K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 5,684 | $66K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.5% | 5,269 | $62K |
| 71250 | 1.5% | 1,132 | $61K | |
| 96367 | 1.0% | 1,408 | $44K | |
| 71045 | Radiologic examination, chest; single view | <1% | 9,734 | $41K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,259 | $40K |
| 73630 | <1% | 3,320 | $40K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,401 | $34K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,233 | $32K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 34,414 | $32K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,036 | $31K |
| 73030 | <1% | 1,825 | $31K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 374 | $29K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 2,581 | $29K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 402 | $27K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,041 | $25K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 284 | $21K |
| 73502 | <1% | 1,085 | $18K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,445 | $18K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 408 | $17K |
| 73610 | <1% | 1,931 | $17K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,780 | $16K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 3,112 | $16K |
| 96376 | <1% | 1,357 | $15K | |
| 73564 | <1% | 972 | $14K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 238 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 29,371 | $9K |
| 83735 | <1% | 8,061 | $9K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 6,087 | $8K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,209 | $8K |
| 84484 | <1% | 5,857 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,138 | $8K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 165 | $6K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,093 | $6K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 448 | $6K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 541 | $5K |
| 72100 | <1% | 253 | $5K | |
| 82607 | <1% | 3,070 | $5K | |
| 80061 | Lipid panel | <1% | 5,651 | $5K |
| 84439 | <1% | 1,834 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,909 | $5K |
| 82043 | <1% | 1,490 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,933 | $4K |
| 95886 | <1% | 160 | $4K | |
| 82728 | <1% | 2,645 | $4K | |
| 87631 | <1% | 3,361 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 673 | $4K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 7,934 | $3K |
| 87186 | <1% | 3,116 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,636 | $3K |
| 81001 | <1% | 7,963 | $3K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,608 | $3K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 50 | $3K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 67 | $3K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,203 | $3K |
| 85610 | <1% | 3,144 | $3K | |
| 86140 | <1% | 3,085 | $3K | |
| 87040 | <1% | 2,737 | $2K | |
| 83880 | <1% | 1,928 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 443 | $2K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 50 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 340 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,717 | $2K |
| 93971 | <1% | 95 | $2K | |
| 93017 | <1% | 97 | $2K | |
| 81003 | <1% | 5,755 | $2K | |
| 80076 | <1% | 1,405 | $2K | |
| 83605 | <1% | 3,519 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,214 | $2K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,584 | $2K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,499 | $2K |
| 76830 | Ultrasound, transvaginal | <1% | 210 | $2K |
| 82803 | <1% | 1,408 | $2K | |
| 73562 | <1% | 226 | $1K | |
| 76642 | <1% | 120 | $1K | |
| 70498 | <1% | 23 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,531 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 2,106 | $1K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,413 | $1K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,844 | $1K |
| 94729 | <1% | 189 | $1K | |
| 94726 | <1% | 191 | $1K | |
| 83550 | <1% | 2,136 | $1K | |
| 73110 | <1% | 111 | $1K | |
| 83540 | <1% | 2,217 | $1K | |
| 99223 | Prolong inpt eval add15 m | <1% | 210 | $991.51 |
| 74178 | <1% | 23 | $967.68 | |
| 85652 | <1% | 1,538 | $920.23 | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 26 | $901.53 |
| 73130 | <1% | 138 | $896.62 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 1,606 | $829.84 |
| 97161 | <1% | 114 | $771.39 | |
| 87077 | <1% | 2,899 | $766.58 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 391 | $742.96 |
| 72110 | <1% | 27 | $730.98 | |
| 77065 | Tomosynthesis, mammo | <1% | 57 | $692.42 |
| 77080 | <1% | 272 | $625.91 | |
| 83690 | <1% | 2,969 | $622.31 | |
| 87070 | <1% | 1,582 | $595.26 | |
| 85378 | <1% | 1,120 | $560.72 | |
| 93226 | <1% | 83 | $546.51 | |
| 73140 | <1% | 66 | $531.93 | |
| 93225 | <1% | 83 | $529.59 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 930 | $507.23 |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 8,106 | $496.93 |
| 85651 | <1% | 1,058 | $482.02 | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 106 | $469.55 |
| 82248 | <1% | 422 | $451.32 | |
| 81002 | <1% | 2,897 | $447.63 | |
| 86850 | <1% | 994 | $420.60 | |
| A9270 | Non-covered item or service | <1% | 1,900 | $402.79 |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 129 | $400.42 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,790 | $392.92 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 435 | $380.41 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 523 | $379.42 |
| 36600 | <1% | 34 | $352.04 | |
| 94200 | <1% | 71 | $321.43 | |
| 97162 | <1% | 28 | $317.92 | |
| 74018 | <1% | 98 | $270.29 | |
| 83921 | <1% | 95 | $226.26 | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 41 | $220.71 |
| 99070 | <1% | 429 | $219.42 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 470 | $198.91 |
| 87205 | <1% | 1,192 | $186.54 | |
| 82550 | <1% | 232 | $186.06 | |
| 87340 | <1% | 137 | $184.75 | |
| 84550 | <1% | 348 | $184.61 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 463 | $168.61 |
| 86901 | <1% | 940 | $157.84 | |
| 86900 | <1% | 887 | $155.30 | |
| 87088 | <1% | 190 | $147.72 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 110 | $143.85 |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,372 | $137.20 |
| 93246 | <1% | 14 | $131.24 | |
| 97597 | <1% | 27 | $120.17 | |
| 80320 | <1% | 263 | $119.80 | |
| 81025 | <1% | 2,056 | $113.90 | |
| 99219 | <1% | 17 | $107.70 | |
| 82784 | <1% | 13 | $94.85 | |
| 85027 | <1% | 104 | $93.40 | |
| 85018 | <1% | 174 | $90.10 | |
| 85014 | <1% | 103 | $85.80 | |
| 85730 | <1% | 68 | $83.16 | |
| 82746 | <1% | 87 | $79.13 | |
| 80047 | <1% | 35 | $74.10 | |
| 99217 | <1% | 37 | $74.01 | |
| 93016 | <1% | 73 | $71.79 | |
| 86038 | <1% | 102 | $70.00 | |
| 84156 | <1% | 125 | $65.27 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 91 | $63.89 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 128 | $59.73 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 70 | $55.61 |
| 83655 | <1% | 100 | $52.19 | |
| 86255 | <1% | 178 | $52.14 | |
| 93227 | <1% | 42 | $48.57 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 15 | $47.89 |
| 83970 | <1% | 55 | $45.01 | |
| 93018 | <1% | 72 | $44.92 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 155 | $39.44 |
| A6449 | Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard | <1% | 55 | $31.84 |
| 82570 | <1% | 12 | $28.84 | |
| 93248 | <1% | 13 | $27.82 | |
| 84100 | <1% | 44 | $27.56 | |
| 84481 | <1% | 12 | $26.98 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 971 | $26.20 |
| 87220 | <1% | 143 | $24.92 | |
| 86803 | <1% | 48 | $23.68 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 17 | $22.10 |
| 86618 | <1% | 12 | $20.36 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 27 | $19.98 |
| 82565 | <1% | 123 | $16.43 | |
| 84703 | <1% | 310 | $16.31 | |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 97 | $10.40 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $9.84 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 71 | $9.83 |
| 77061 | <1% | 25 | $8.54 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 103 | $7.93 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 128 | $6.15 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 129 | $6.15 |
| 82805 | <1% | 90 | $5.23 | |
| 84132 | <1% | 17 | $4.54 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 13 | $3.76 |
| 87081 | <1% | 379 | $3.70 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 256 | $2.05 |
| 86592 | <1% | 246 | $0.46 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 50 | $0.36 |
| 99000 | <1% | 77 | $0.16 | |
| 82150 | <1% | 60 | $0.16 | |
| 87147 | <1% | 96 | $0.10 | |
| 0031A | 0% | 319 | $0.00 | |
| J3490 | Unclassified drugs | 0% | 617 | $0.00 |
| 0012A | 0% | 357 | $0.00 | |
| 91301 | 0% | 205 | $0.00 | |
| 86701 | 0% | 114 | $0.00 | |
| 0011A | 0% | 345 | $0.00 | |
| 99024 | 0% | 183 | $0.00 | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 0% | 44 | $0.00 |
| 0001A | 0% | 46 | $0.00 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 0% | 45 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 21 | $0.00 |
| 91303 | 0% | 58 | $0.00 | |
| J1815 | Injection, insulin, per 5 units | 0% | 19 | $0.00 |
| 85007 | 0% | 13 | $0.00 | |
| 0002A | 0% | 13 | $0.00 | |
| 59025 | Fetal non-stress test | 0% | 283 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 52 | $0.00 |
| 84520 | 0% | 27 | $0.00 | |
| 87653 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZEWE, JEFF (CEO)
| Provider | Location | Paid |
|---|---|---|
| Houlton Regional Hospital | Houlton, ME | $6.99M |
| Houlton Regional Hospital | Houlton, ME | $3.10M |
| Houlton Regional Hospital | Houlton, ME | $32K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.